Publications & Previous Studies

Previous Studies

The CamT1D team have recently completed two early phase clinical studies looking at the use of Aldesleukin (Interleukin-2) as a potential new treatment for type 1 diabetes. DILT1D was a dose finding study and DILfrequency determined the most effective dosing strategy for treatment.

Previous Studies

Study Publications

For more information or data access agreements please contact the study team via the ‘get in touch’ link on this page.

Type 1 diabetes is the most common severe chronic autoimmune disease worldwide and the incidence of the disease is rising rapidly.

Type 1 diabetes causes the immune system to mistake cells in the pancreas as harmful and attack them.

When these cells are damaged the pancreas is unable to produce insulin, which plays an essential role in transferring glucose out of the bloodstream and into cells to be converted into energy.

The management of type 1 diabetes usually involves measuring the amount of glucose in the blood and injecting artificial insulin to make up for the insulin the pancreas is not producing.

The DILT1D research study investigated a potential new medication for type 1 diabetes, using a drug called aldesleukin (interleukin-2).

The research team investigated whether this medication can rebalance the immune system in order to allow remission of the autoimmunity. It is hoped this will help to preserve the remaining ?eta cells of the pancreas in people with newly diagnosed type 1 diabetes and if so, what dose of the medication is required to obtain the best results.

The DILT1D team was led by the chief investigator Dr Frank Waldron-Lynch, to watch him talk about the trial and the importance of the research watch this short video.

This research study investigated a potential new medication for use in type 1 diabetes, using a drug called aldesleukin (interleukin-2).

The research team are investigating whether this medication can halt the damage to the pancreas of people with newly diagnosed type 1 diabetes and if so, how often is the drug required for the best results.

The DILfrequency team was led by the chief investigator Dr Frank Waldron-Lynch, to watch a short film from CambridgeTV about the trial and the importance of the research see below.

The protocol for the DILfrequency clinical study was published at the commencement of the study.

Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D).